Glioblastoma News and Research

RSS

Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.

Celldex reports net loss of $6.6 million for first-quarter 2010

Celldex Therapeutics, Inc. today reported financial results for the first quarter ended March 31, 2010. Celldex reported a net loss of $6.6 million, or $0.21 per share, for the first quarter of 2010 compared to a net loss of $7.7 million, or $0.49 per share, for the first quarter of 2009. At March 31, 2010, Celldex reported cash, cash equivalents and marketable securities of $75.4 million, which the Company believes will be sufficient to meet estimated working capital requirements and fund operations into 2012.

4 May 2010

Personalized vaccine processed using tumor tissue promising for brain tumor treatment

Each day in the United States, 482 people are diagnosed with a brain tumor. For these 482 people, not many treatments exist. With the current treatments available, only 5% of those diagnosed with a Glioblastoma Multiform will survive more than 5 years. Only two new treatments have been approved by the FDA in the past two decades.

4 May 2010

Novel combined immunotherapy promising for treatment of malignant brain tumors

A new Phase I clinical trial conducted at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Institute in Los Angeles shows that two innovative treatment approaches may safely be combined to treat patients with highly aggressive, malignant brain tumors called gliomas. The results suggest that combining the two therapies might boost their effectiveness and supports the pursuit of additional studies on this approach to treating these tumors.

4 May 2010

QIAGEN reports 20% revenue growth in first quarter 2010

QIAGEN N.V. today announced the results of operations for its quarter ended March 31, 2010. Net sales were at the high end of, and adjusted earnings per share for the first quarter 2010 exceeded the guidance provided by the Company on February 9, 2010.

From QIAGEN Manchester Limited 4 May 2010

Interim study results demonstrate anti-tumor activity of CytRx's INNO-206 in myeloma tumor cells

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced interim study results that showed its doxorubicin prodrug INNO-206 demonstrated statistically significant anti-tumor activity in human myeloma tumor cells growing in immune-deficient mice compared to a control group, while exhibiting significantly less toxicity than doxorubicin even though INNO-206 was administered at much higher doses.

3 May 2010

ImmunoCellular Therapeutics seeks FDA orphan drug status for ICT-107 dendritic-cell based vaccine for GBM

ImmunoCellular Therapeutics announced today it has filed an orphan drug application with the U.S. Food and Drug Administration (FDA) for its cancer treatment candidate ICT-107. ICT-107 is a dendritic-cell based cancer vaccine product which targets glioblastoma multiforme (GBM), the most prevalent, aggressive and malignant form of primary brain tumors.

3 May 2010

Researchers experiment different nanoparticles that may help surgeons remove glioblastomas

Researchers have developed a way to enhance how brain tumors appear in MRI scans and during surgery, making the tumors easier for surgeons to identify and remove.

30 Apr 2010

SCOLR Pharma first-quarter total revenues decrease 3%

SCOLR Pharma, Inc. today reported financial results for the first three months ended March 31, 2010.

30 Apr 2010

Continuing education lectures on adult glioblastoma to be held at all U.S. healthcare centers

Adult glioblastoma continues to be a difficult disease to treat, so healthcare professionals must have the most up-to-date information regarding optimal methods for diagnostic imaging and treatment of these tumors. Awareness of novel agents in clinical trials is also critical to providing the best care.

30 Apr 2010

Geron reports net loss of $16.6M for first-quarter 2010

Geron Corporation today reported financial results for the three months ended March 31, 2010.

29 Apr 2010

Study links progression of lethal type of brain tumor with reduced expression of immune system genes

A new study links progression of a lethal type of brain tumor with reduced expression of more than 600 immune system genes, suggesting how complex the immune response is to the cancer and the resulting difficulty in targeting specific immune system proteins for treatment.

27 Apr 2010

Karolinska University Hospital acquires Leksell Gamma Knife Perfexion fifth generation radiosurgery system

Prof. Lars Leksell (1907-1986), inventor of the radiosurgical instrument that bears his name and a faculty member of Karolinska University Hospital (Solna, Sweden), performed the world's first Gamma Knife® surgery at nearby Sophiahemmet Hospital, the location of the first Leksell Gamma Knife. Karolinska University Hospital recently acquired Elekta's fifth generation radiosurgery system, Leksell Gamma Knife® Perfexion™.

24 Apr 2010

Karolinska University Hospital acquires Elekta's fifth generation radiosurgery system

Prof. Lars Leksell (1907-1986), inventor of the radiosurgical instrument that bears his name and a faculty member of Karolinska University Hospital (Solna, Sweden), performed the world's first Gamma Knife surgery at nearby Sophiahemmet Hospital, the location of the first Leksell Gamma Knife. Karolinska University Hospital recently acquired Elekta's fifth generation radiosurgery system, Leksell Gamma Knife Perfexion.

24 Apr 2010

Geron scientists highlight importance of telomerase inhibitor, GRN163L at AACR 2010

Geron Corporation today announced five presentations by Geron scientists and collaborators on the company's telomerase inhibitor, imetelstat sodium, including the drug's activity against cancer stem cells, at the 101st American Association for Cancer Research annual meeting held in Washington D.C.

23 Apr 2010

ImmunoCellular Therapeutics, UPENN sign research agreement

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today that the Company has entered into a sponsored research agreement and an option agreement with The University of Pennsylvania to support process development and manufacturing in a planned Phase II clinical trial of ICT-107, the Company's dendritic-cell based cancer vaccine product candidate for the treatment of glioblastoma multiforme.

22 Apr 2010

Preclinical data of ANG1005 and ANG1007 for treatment of brain cancer presented at AACR 2010

Angiochem, Inc., a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier through LRP-1 targeting, announced today that preclinical data was presented on two of its oncology programs, ANG1005 and ANG1007, for the treatment of brain cancers at the 101st Annual meeting of the American Association for Cancer Research 2010, April 17-21, in Washington, DC.

21 Apr 2010

Plexxikon presents promising preclinical data from PLX3397 in vivo cancer studies

Plexxikon Inc. today announced promising preclinical data from in vivo cancer studies with PLX3397 demonstrating significant reduction in tumor burden, metastatic spread, bone erosion and cancer bone pain. PLX3397 is an oral, selective kinase inhibitor that down-modulates macrophages, microglia, osteoclasts and mast cells, all cell types targeted by this drug candidate. These cell types play a key role in cancer and metastasis.

21 Apr 2010

Gemin X Pharmaceuticals closes $16 million Series D financing

Gemin X Pharmaceuticals, a clinical stage biopharmaceutical company developing novel, targeted cancer therapeutics, today announced the close of its $16 million Series D round of financing. Current investors Caxton Advantage Life Sciences Fund LP and Sanderling Venture Partners co-led the round. In addition, the Series D structure grants certain current investors the option to invest an additional $4 million in this financing round in the future.

21 Apr 2010

CytRx' bafetinib receives EMEA COMP positive opinion for treatment of CML

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that bafetinib (formerly known as INNO-406) has received official notification from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMEA) that a positive opinion was made regarding the application for orphan medicinal product for the treatment of chronic myeloid leukemia (CML).

20 Apr 2010

Myriad Pharmaceuticals terminates merger agreement with Javelin Pharmaceuticals

Myriad Pharmaceuticals, Inc. today announced the termination, effective as of Friday, April 16, 2010, of its merger agreement with Javelin Pharmaceuticals.

19 Apr 2010

Glioblastoma News and Research

Further Reading

Celldex reports net loss of $6.6 million for first-quarter 2010

Personalized vaccine processed using tumor tissue promising for brain tumor treatment

Novel combined immunotherapy promising for treatment of malignant brain tumors

QIAGEN reports 20% revenue growth in first quarter 2010

Interim study results demonstrate anti-tumor activity of CytRx's INNO-206 in myeloma tumor cells

ImmunoCellular Therapeutics seeks FDA orphan drug status for ICT-107 dendritic-cell based vaccine for GBM

Researchers experiment different nanoparticles that may help surgeons remove glioblastomas

SCOLR Pharma first-quarter total revenues decrease 3%

Continuing education lectures on adult glioblastoma to be held at all U.S. healthcare centers

Geron reports net loss of $16.6M for first-quarter 2010

Study links progression of lethal type of brain tumor with reduced expression of immune system genes

Karolinska University Hospital acquires Leksell Gamma Knife Perfexion fifth generation radiosurgery system

Karolinska University Hospital acquires Elekta's fifth generation radiosurgery system

Geron scientists highlight importance of telomerase inhibitor, GRN163L at AACR 2010

ImmunoCellular Therapeutics, UPENN sign research agreement

Preclinical data of ANG1005 and ANG1007 for treatment of brain cancer presented at AACR 2010

Plexxikon presents promising preclinical data from PLX3397 in vivo cancer studies

Gemin X Pharmaceuticals closes $16 million Series D financing

CytRx' bafetinib receives EMEA COMP positive opinion for treatment of CML

Myriad Pharmaceuticals terminates merger agreement with Javelin Pharmaceuticals

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News